Europe Proteomics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
The Europe proteomics market was valued at approximately USD 5,356 million in 2020, and it is expected to witness a revenue of USD 10,793 million in 2026, with a CAGR of 12.4% over the forecast period, 2021-2026.
The COVID-19 pandemic has turned the spotlight on proteomic studies, and thus, it is expected to drive the studied market growth during the present crisis. According to the research article published in the Journal of Proteins and Proteomics, 2020, proteomics and metabolomics are the fields with vast potential to face the current COVID-19 challenge. The SARS-CoV genome encodes 28 proteins of which the structure of 16 proteins or their functional domain has been determined to date. Of these 16 proteins, eight them have novel functional domains that indicate the distinctiveness of coronavirus proteins. The proteomics aids in the identification of the novel biomarkers of the SARS-CoV2 virus, and thus, provides effective opportunities for the point-of-care clinical healthcare deliveries in the most cost-effective manner. Additionally, as per the research article published in Immunity, 2020, the host responses to COVID-19 were profiled by performing plasma proteomics of a cohort of COVID-19 patients and developing a machine-learning-based pipeline to identify 11 proteins as biomarkers, and thus, shed light on potential therapeutic targets of COVID-19. Thus, given the aforementioned applications of proteomics, the COVID-19 pandemic has a positive impact on the growth of the studied market.
Proteomics has received great attention over the last decade, particularly in the field of diagnosis, drug research, and development. It has various applications ranging from identification of proteins to purification and separation of the protein to study the nature and properties. It has vast applications in identifying some protein-related disorders or diseases in the organism. Thus, it is evolving into an important tool in the field of life sciences.
Furthermore, increasing demand for personalized medicine in Europe, along with the presence of key market players such as Merck KGaA, is expected to boost regional growth. Also, positive support from the local authorities in Europe and initiatives by research organizations to advance the proteomics technologies such as chemo proteomics and spectrometry are expected to further fuel the market growth. For instance, in August 2020, Bruker Corporation agreed on a strategic collaboration with Utrecht University to work on the study of the 3D structures and interactions of proteins using mass spectrometry. Also, in January 2019, the European Union granted EUR 10 million to a consortium of eighteen European research groups in the field of mass spectrometry-based proteomics research throughout Europe. Thus, the increasing investment by key players and funding to the research organizations for the advancements in the field of proteomics in Europe are expected to drive the proteomics market growth significantly over the forecast period.
Key Market TrendsThe Drug Discovery Segment is Expected to Have a Notable Growth Rate over the Forecast Period in EuropeThe identification of novel and effective therapeutics in the treatment of disease has been considered one of the most ongoing developments in the study of human genes and proteins. This process of identification and development is based on genome and proteome information for the detection of proteins associated with a disease, which are later used as targets for new drugs by implementing software technologies.
The growing spending on drug discovery and development by the pharma and biopharmaceutical companies, along with research organizations in the region, is the primary factor for the segment growth over the forecast period.
The impact of COVID-19 on the proteomics market aimed at drug discovery is expected to be significant due to the emerging research activities pertaining to the development of novel drugs in the treatment of COVID-19 infection in the region. In August 2020, the European Consortium was launched to accelerate the research, discovery, and development of immediately required drugs for the treatment of SARS-CoV2 viral infection. Hence, this increases the demand for proteomic based studies, which subsequently drives the studied market during the pandemic.
According to the research article published in Proteomics: Clinical Applications, 2019, the advancements in proteomics, such as the development of thermal proteome profiling, enable comprehensive drug target profiling and contribute to a high value in drug discovery. Additionally, the increasing research funding and ongoing projects by research institutes and major players in Europe, especially in the United Kingdom, drive the demand in the studied market. For instance, in December 2020, the UK Biobank collaborated with Biopharma Consortium comprising ten biopharmaceutical companies, on the Pharma Proteomics Project, for a better understanding of disease processes and supporting innovative drug development. Thus, given the increasing research activities in drug discovery in the European region, the proteomics market is expected to witness significant growth over the forecast period.
Competitive LandscapeThe European proteomics market is moderately consolidated and consists of a few major players. Companies like Agilent Technologies Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Danaher Corporation, Merck KGaA, Promega Corporation, Thermo Fisher Scientific Inc., and Waters Corporation are the key players, among others. The companies are involved in various strategies such as new product launches and investments in R&D activities to sustain in the highly competitive environment.
Additional Benefits:Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook